|
WO2004046160A2
(en)
|
2002-11-18 |
2004-06-03 |
Santaris Pharma A/S |
Amino-lna, thio-lna and alpha-l-oxy-ln
|
|
KR101773551B1
(ko)
|
2008-10-15 |
2017-08-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
인자 １１ 발현의 조정
|
|
CN102282155B
(zh)
|
2008-12-02 |
2017-06-09 |
日本波涛生命科学公司 |
磷原子修饰的核酸的合成方法
|
|
RU2612521C2
(ru)
|
2009-07-06 |
2017-03-09 |
Онтории, Инк. |
Новые пролекарства нуклеиновых кислот и способы их применения
|
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
|
CA2817960C
(en)
|
2010-11-17 |
2020-06-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
CN103796657B
(zh)
|
2011-07-19 |
2017-07-11 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
|
AU2012308320C1
(en)
|
2011-09-14 |
2018-08-23 |
Translate Bio Ma, Inc. |
Multimeric oligonucleotide compounds
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
SG11201407483YA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
|
EA201492122A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии utrn
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
KR102213609B1
(ko)
|
2012-07-13 |
2021-02-08 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
PL2872485T3
(pl)
|
2012-07-13 |
2021-05-31 |
Wave Life Sciences Ltd. |
Asymetryczna grupa pomocnicza
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
CN104837996A
(zh)
|
2012-11-15 |
2015-08-12 |
罗氏创新中心哥本哈根有限公司 |
抗apob反义缀合物化合物
|
|
AU2014211406B2
(en)
*
|
2013-01-30 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
LNA oligonucleotide carbohydrate conjugates
|
|
US9506030B2
(en)
|
2013-05-01 |
2016-11-29 |
Regulus Therapeutics Inc. |
Compounds and methods for enhanced cellular uptake
|
|
SG10201803157XA
(en)
|
2013-05-01 |
2018-05-30 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
DK2992098T3
(da)
|
2013-05-01 |
2019-06-17 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
US9994846B2
(en)
|
2013-10-25 |
2018-06-12 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
BR112016016400A2
(pt)
|
2014-01-16 |
2017-10-03 |
Wave Life Sciences Ltd |
Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
|
|
CA2935426C
(en)
*
|
2014-01-30 |
2023-07-25 |
F. Hoffmann-La Roche Ag |
Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
|
|
EP3119888B1
(en)
|
2014-03-19 |
2021-07-28 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
HUE050704T2
(hu)
|
2014-04-01 |
2020-12-28 |
Biogen Ma Inc |
Összetételek a SOD-1 expressziójának modulálására
|
|
BR112016022742B1
(pt)
|
2014-05-01 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Composto químico, composição compreendendo o composto e uso dos mesmos
|
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
|
EA036496B1
(ru)
|
2014-05-01 |
2020-11-17 |
Ионис Фармасьютикалз, Инк. |
Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
|
|
US9382540B2
(en)
|
2014-05-01 |
2016-07-05 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
KR20170033439A
(ko)
|
2014-08-07 |
2017-03-24 |
레굴루스 테라퓨틱스 인크 |
대사 장애에 대한 마이크로rna의 표적화
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
CN106795200B
(zh)
|
2014-10-10 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
Galnac亚磷酰胺、其核酸缀合物及其用途
|
|
KR20170081257A
(ko)
*
|
2014-11-10 |
2017-07-11 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
C형 간염에 대한 조합 장기 작용 조성물 및 방법
|
|
US10815481B2
(en)
|
2014-12-16 |
2020-10-27 |
Roche Innovation Center Copenhagen A/S |
Chiral library screen
|
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｒｅｖｅｒｓｉｒ（商標）化合物
|
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
US10758558B2
(en)
|
2015-02-13 |
2020-09-01 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
RS62672B1
(sr)
|
2015-04-03 |
2021-12-31 |
Univ Massachusetts |
Oligonukleotidna jedinjenja za tretman preeklampsije i drugih angiogenskih poremećaja
|
|
MX2017012426A
(es)
|
2015-04-03 |
2018-01-26 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de tmprss6.
|
|
US20160319278A1
(en)
|
2015-04-03 |
2016-11-03 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
PL3277814T3
(pl)
|
2015-04-03 |
2020-11-30 |
University Of Massachusetts |
Związki oligonukleotydowe ukierunkowane na mrna huntingtyny
|
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
WO2017030973A1
(en)
*
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
JP6835826B2
(ja)
|
2015-08-24 |
2021-02-24 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｌｎａ−ｇプロセス
|
|
US20210052631A1
(en)
*
|
2015-09-25 |
2021-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
US10577388B2
(en)
|
2015-10-02 |
2020-03-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
IL295755A
(en)
|
2015-10-09 |
2022-10-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
PL4119569T3
(pl)
*
|
2015-11-06 |
2024-11-18 |
Ionis Pharmaceuticals, Inc. |
Sprzężone związki antysensowne do zastosowania w terapii
|
|
LT3374509T
(lt)
|
2015-11-12 |
2021-03-10 |
F. Hoffmann-La Roche Ag |
Oligonukleotidai, skirti sukelti iš tėvo paveldėto ube3a raišką
|
|
EP3389670A4
(en)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
METHODS OF TREATING BREAST CANCER
|
|
AU2016381174A1
(en)
|
2015-12-31 |
2018-05-31 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing Ataxin-2 expression
|
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
|
AU2017213404A1
(en)
*
|
2016-01-29 |
2018-09-20 |
Kyowa Kirin Co., Ltd. |
Nucleic acid conjugate
|
|
US10478503B2
(en)
|
2016-01-31 |
2019-11-19 |
University Of Massachusetts |
Branched oligonucleotides
|
|
CA3011946A1
(en)
|
2016-03-07 |
2017-09-14 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
RU2747822C2
(ru)
*
|
2016-03-14 |
2021-05-14 |
Ф. Хоффманн-Ля Рош Аг |
Олигонуклеотиды для понижения экспрессии pd-l1
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
EP3429690A4
(en)
|
2016-03-16 |
2019-10-23 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR MODULATING KEAP1
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
EP3228326A1
(en)
*
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
|
EP3825400B1
(en)
*
|
2016-04-08 |
2024-12-25 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
|
WO2017192820A1
(en)
|
2016-05-06 |
2017-11-09 |
Ionis Pharmaceuticals, Inc. |
Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
|
|
EP4219767A1
(en)
|
2016-06-17 |
2023-08-02 |
F. Hoffmann-La Roche AG |
Papd5 and papd7 inhibitors for treating a hepatitis b infection
|
|
AU2017286811A1
(en)
|
2016-06-17 |
2018-11-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
WO2017220751A1
(en)
|
2016-06-22 |
2017-12-28 |
Proqr Therapeutics Ii B.V. |
Single-stranded rna-editing oligonucleotides
|
|
MX2018015722A
(es)
|
2016-07-01 |
2019-05-27 |
Hoffmann La Roche |
Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1).
|
|
CA3033368A1
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
CN110352244B
(zh)
|
2016-09-01 |
2023-03-21 |
ProQR治疗上市公司Ⅱ |
化学修饰的编辑rna的单链寡核苷酸
|
|
SG11201901841TA
(en)
|
2016-09-02 |
2019-03-28 |
Arrowhead Pharmaceuticals Inc |
Targeting ligands
|
|
US11400161B2
(en)
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
EP3568477A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
WO2018130584A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
EP3568479A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
EP3568478A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
US20190345496A1
(en)
|
2017-01-13 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
WO2018165541A1
(en)
|
2017-03-10 |
2018-09-13 |
The Board Of Regents Of The University Of Texas System |
Treatment of fuchs' endothelial corneal dystrophy
|
|
EP3594346A4
(en)
|
2017-03-10 |
2020-12-16 |
National Center For Child Health And Development |
ANTISENS OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYPE IA GLYCOGEN STORAGE DISEASE
|
|
MX2019012280A
(es)
|
2017-04-11 |
2020-01-23 |
Arbutus Biopharma Corp |
Composiciones dirigidas.
|
|
WO2018215049A1
(en)
*
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
US11273222B2
(en)
|
2017-05-26 |
2022-03-15 |
National Cerebral And Cardiovascular Center |
Antisense nucleic acid targeting PCSK9
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
CN120330183A
(zh)
*
|
2017-06-02 |
2025-07-18 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
WO2018226788A1
(en)
|
2017-06-07 |
2018-12-13 |
University Of Massachusetts |
Anti-adam33 oligonucleotides and related methods
|
|
JP7406793B2
(ja)
|
2017-06-23 |
2023-12-28 |
ユニバーシティー オブ マサチューセッツ |
２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
|
|
EP3668600B1
(en)
|
2017-08-10 |
2024-05-15 |
Abionyx Pharma SA |
Cargomers
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
JP2020531450A
(ja)
|
2017-08-17 |
2020-11-05 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
調整性ｒｅｖｅｒｓｉｒ（商標）化合物
|
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
EP3694530A4
(en)
*
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
EP3694995A1
(en)
|
2017-10-13 |
2020-08-19 |
Roche Innovation Center Copenhagen A/S |
Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
|
|
CN111511914B
(zh)
|
2017-10-16 |
2023-11-17 |
豪夫迈·罗氏有限公司 |
减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
|
|
CN117105811B
(zh)
|
2017-11-06 |
2025-12-12 |
日东电工株式会社 |
用于递送生物活性分子的膜融合化合物
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
CN110944675B9
(zh)
|
2017-12-01 |
2024-08-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CA3083970A1
(en)
|
2017-12-01 |
2019-06-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
|
|
EP3719126B1
(en)
|
2017-12-01 |
2025-01-01 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
EP3719127A4
(en)
|
2017-12-01 |
2021-10-20 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
|
|
DK3719128T3
(da)
|
2017-12-01 |
2025-03-03 |
Suzhou Ribo Life Science Co Ltd |
Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
|
|
AU2018378812B2
(en)
|
2017-12-06 |
2025-05-22 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
US11459564B2
(en)
|
2017-12-21 |
2022-10-04 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
WO2019121838A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for htra1 rna antagonists
|
|
WO2019122279A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
CA3084170A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
US11597926B2
(en)
|
2017-12-22 |
2023-03-07 |
Roche Innovation Center Copenhagen A/S |
Thiophosphoramidites
|
|
AU2018394875B2
(en)
*
|
2017-12-29 |
2023-08-03 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
US20210095274A1
(en)
|
2018-01-10 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
|
WO2019137974A1
(en)
|
2018-01-12 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
|
CN120310791A
(zh)
|
2018-01-12 |
2025-07-15 |
百时美施贵宝公司 |
靶向α-突触核蛋白的反义寡核苷酸及其用途
|
|
SG11202006142PA
(en)
|
2018-01-12 |
2020-07-29 |
Roche Innovation Ct Copenhagen As |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
|
SG11202006528XA
(en)
|
2018-01-12 |
2020-08-28 |
Bristol Myers Squibb Co |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
AU2019206731A1
(en)
|
2018-01-15 |
2020-07-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of DNM2 expression
|
|
CN111615558A
(zh)
|
2018-01-17 |
2020-09-01 |
罗氏创新中心哥本哈根有限公司 |
用于调节erc1表达的寡核苷酸
|
|
CN111655851A
(zh)
|
2018-01-18 |
2020-09-11 |
哥本哈根罗氏创新中心 |
靶向srebp1的反义寡核苷酸
|
|
AU2019212849B2
(en)
*
|
2018-01-26 |
2024-02-29 |
F. Hoffmann-La Roche Ag |
Radiolabelled oligonucleotides and process for their preparation
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
BR112020016170A2
(pt)
*
|
2018-02-09 |
2020-12-15 |
Genentech, Inc. |
Oligonucleotídeos terapêutico e antissenso, conjugado, sal farmaceuticamente aceitável, composição farmacêutica, método in vitro ou in vivo para modular a expressão de tmem106b, método para tratar ou prevenir uma doença, uso do oligonucleotídeo e uso ou método
|
|
MX2020008581A
(es)
|
2018-02-21 |
2020-09-21 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.
|
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
KR102398295B1
(ko)
|
2018-03-09 |
2022-05-17 |
다이이찌 산쿄 가부시키가이샤 |
당원병 Ia형 치료약
|
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
SG11202009680XA
(en)
|
2018-04-05 |
2020-10-29 |
Hoffmann La Roche |
Use of fubp1 inhibitors for treating hepatitis b virus infection
|
|
SG11202008660TA
(en)
|
2018-04-11 |
2020-10-29 |
Ionis Pharmaceuticals Inc |
Modulators of ezh2 expression
|
|
CN112105745A
(zh)
|
2018-05-07 |
2020-12-18 |
罗氏创新中心哥本哈根有限公司 |
用于寡核苷酸治疗剂的大规模平行发现方法
|
|
US12005120B2
(en)
|
2018-05-08 |
2024-06-11 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
CU20200082A7
(es)
|
2018-05-09 |
2021-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la reducción de la expresión de fxi
|
|
EP4663758A3
(en)
|
2018-05-09 |
2026-04-29 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
|
JP7665509B2
(ja)
*
|
2018-05-11 |
2025-04-21 |
アルファ アノマリック エスアエス |
７’－５’－アルファ－アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート
|
|
US12391942B2
(en)
|
2018-05-11 |
2025-08-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
JP7379387B2
(ja)
|
2018-06-05 |
2023-11-14 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
|
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
PE20210346A1
(es)
|
2018-07-03 |
2021-02-25 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de tau
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
CN112534055A
(zh)
|
2018-07-13 |
2021-03-19 |
豪夫迈·罗氏有限公司 |
用于调节rtel1表达的寡核苷酸
|
|
US12496311B2
(en)
|
2018-07-17 |
2025-12-16 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
AR115847A1
(es)
|
2018-07-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de la atxn2
|
|
EP4122943B1
(en)
|
2018-07-31 |
2024-05-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
BR112020025272A2
(pt)
*
|
2018-07-31 |
2021-03-09 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
|
|
WO2020033899A1
(en)
|
2018-08-10 |
2020-02-13 |
University Of Massachusetts |
Modified oligonucleotides targeting snps
|
|
WO2020038377A1
(zh)
|
2018-08-21 |
2020-02-27 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
CN112585280A
(zh)
|
2018-08-23 |
2021-03-30 |
罗氏创新中心哥本哈根有限公司 |
微小rna-134生物标志物
|
|
US11279930B2
(en)
|
2018-08-23 |
2022-03-22 |
University Of Massachusetts |
O-methyl rich fully stabilized oligonucleotides
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
WO2020043750A1
(en)
|
2018-08-28 |
2020-03-05 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
WO2020051398A1
(en)
*
|
2018-09-06 |
2020-03-12 |
Aptamir Therapeutics, Inc. |
Metabolic benefits of short mir-22 mirna antagomir therapies
|
|
US11896674B2
(en)
|
2018-09-30 |
2024-02-13 |
Suzhou Ribo Life Science Co., Ltd. |
SiRNA conjugate, preparation method therefor and use thereof
|
|
JP2022512877A
(ja)
|
2018-11-01 |
2022-02-07 |
エフ．ホフマン－ラ ロシュ アーゲー |
Ｔｉａ１を標的とするアンチセンスオリゴヌクレオチド
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
CR20210311A
(es)
|
2018-11-15 |
2021-07-22 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresión de irf5
|
|
US12281305B2
(en)
|
2018-11-21 |
2025-04-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing prion expression
|
|
WO2020117706A1
(en)
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
|
AU2019406186A1
(en)
|
2018-12-20 |
2021-07-15 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of KCNT1 related disorders
|
|
WO2020136125A2
(en)
|
2018-12-21 |
2020-07-02 |
Boehringer Ingelheim International Gmbh |
Antisense oligonucleotides targeting card9
|
|
WO2020135673A1
(zh)
|
2018-12-28 |
2020-07-02 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN113614232A
(zh)
*
|
2019-01-18 |
2021-11-05 |
马萨诸塞大学 |
动态药代动力学修饰锚
|
|
EP3914232A1
(en)
*
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
|
BR112021013369A2
(pt)
|
2019-01-31 |
2021-09-21 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de yap1
|
|
TW202102516A
(zh)
|
2019-02-20 |
2021-01-16 |
丹麥商羅氏創新中心哥本哈根有限公司 |
膦醯基乙酸酯間隙子寡核苷酸
|
|
TW202045521A
(zh)
|
2019-02-20 |
2020-12-16 |
丹麥商羅氏創新中心哥本哈根有限公司 |
新穎亞磷醯胺化物
|
|
JP7503072B2
(ja)
|
2019-02-26 |
2024-06-19 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドの製剤化方法
|
|
AU2020227824B2
(en)
|
2019-02-27 |
2025-07-10 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
|
CN113507942A
(zh)
*
|
2019-03-05 |
2021-10-15 |
豪夫迈·罗氏有限公司 |
分子的细胞内靶向
|
|
PT3947684T
(pt)
|
2019-03-29 |
2025-05-19 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular ube3a‑ats
|
|
US20220177894A1
(en)
|
2019-04-02 |
2022-06-09 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for immunotherapy
|
|
EP3947680A2
(en)
|
2019-04-03 |
2022-02-09 |
Bristol-Myers Squibb Company |
Angptl2 antisense oligonucleotides and uses thereof
|
|
EP3947677A1
(en)
|
2019-04-04 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating atxn2 expression
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
US12590304B2
(en)
|
2019-05-22 |
2026-03-31 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
KR20220011689A
(ko)
|
2019-05-22 |
2022-01-28 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
|
|
AU2020280439B2
(en)
|
2019-05-22 |
2025-08-14 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
CN113795582B
(zh)
|
2019-05-24 |
2024-05-24 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
SG11202112741XA
(en)
|
2019-05-31 |
2021-12-30 |
Aligos Therapeutics Inc |
Modified gapmer oligonucleotides and methods of use
|
|
CN113950529A
(zh)
|
2019-06-06 |
2022-01-18 |
豪夫迈·罗氏有限公司 |
靶向atxn3的反义寡核苷酸
|
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
JP2022543191A
(ja)
*
|
2019-07-30 |
2022-10-11 |
エムペグ エルエイ リミテッド ライアビリティ カンパニー |
増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達
|
|
KR20220047989A
(ko)
|
2019-08-09 |
2022-04-19 |
유니버시티 오브 매사추세츠 |
Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
|
|
IL291251B1
(en)
|
2019-09-10 |
2026-02-01 |
Daiichi Sankyo Co Ltd |
Oligonucleotide-galnac conjugate for targeted delivery to the liver and method for its production
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
IL291917A
(en)
*
|
2019-10-02 |
2022-06-01 |
Sirnaomics Inc |
Oligonucleotides with nucleoside analogs, compositions comprising same and uses thereof
|
|
WO2021122869A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of scamp3 inhibitors for treating hepatitis b virus infection
|
|
EP4077669A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of sbds inhibitors for treating hepatitis b virus infection
|
|
EP4058032A4
(en)
*
|
2019-12-19 |
2024-01-10 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
JP2023506954A
(ja)
|
2019-12-19 |
2023-02-20 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
|
|
WO2021122735A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of sept9 inhibitors for treating hepatitis b virus infection
|
|
WO2021122921A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of cops3 inhibitors for treating hepatitis b virus infection
|
|
EP4077672A1
(en)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Enhanced oligonucleotides for inhibiting scn9a expression
|
|
MX2022007908A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
|
|
EP4081217A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
WO2021152005A1
(en)
|
2020-01-28 |
2021-08-05 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
CN120505310A
(zh)
|
2020-02-28 |
2025-08-19 |
Ionis制药公司 |
用于调节smn2的化合物和方法
|
|
EP4110916A1
(en)
|
2020-02-28 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating cd73 exon 7 splicing
|
|
GB2613225B
(en)
|
2020-03-04 |
2024-01-03 |
Verve Therapeutics Inc |
Compositions and methods for targeted RNA delivery
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
CN115916262A
(zh)
*
|
2020-04-21 |
2023-04-04 |
旗舰创业股份有限公司 |
双官能分子及其使用方法
|
|
TWI901676B
(zh)
|
2020-05-01 |
2025-10-21 |
美商Ionis製藥公司 |
調節ａｔｘｎ１之化合物及方法
|
|
JP2023525770A
(ja)
|
2020-05-11 |
2023-06-19 |
ジェネンテック， インコーポレイテッド |
神経学的疾患を処置するための補体ｃ４阻害剤および関連する組成物、ならびにそれを使用するシステムおよび方法
|
|
WO2021231210A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
EP4149486A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
WO2021229036A1
(en)
|
2020-05-13 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Oligonucleotide agonists targeting progranulin
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
CN115884777A
(zh)
|
2020-05-22 |
2023-03-31 |
豪夫迈·罗氏有限公司 |
用于card9的剪接调节的寡核苷酸
|
|
WO2021242883A1
(en)
|
2020-05-26 |
2021-12-02 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
US20230212572A1
(en)
|
2020-06-09 |
2023-07-06 |
Roche Innovation Center Copenhagen A/S |
Guanosine Analogues for Use in Therapeutics Polynucleotides
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
EP4172338A4
(en)
|
2020-06-29 |
2025-06-11 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING PLP1
|
|
JP2023534557A
(ja)
|
2020-07-23 |
2023-08-09 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
CA3189922A1
(en)
|
2020-07-28 |
2022-02-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing app expression
|
|
CN111671913B
(zh)
*
|
2020-07-30 |
2022-02-08 |
四川大学 |
一种量子点-小核酸偶联物及其用途
|
|
IL300258A
(en)
|
2020-08-07 |
2023-03-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating SCN2A
|
|
CN116157522A
(zh)
|
2020-08-21 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
EP4196102A1
(en)
*
|
2020-10-02 |
2023-06-21 |
Sirnaomics, Inc. |
NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES
|
|
LT4136092T
(lt)
|
2020-11-18 |
2024-09-25 |
Ionis Pharmaceuticals, Inc. |
Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui
|
|
AR124229A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
|
US20230060373A1
(en)
|
2020-12-03 |
2023-03-02 |
Hoffmann-La Roche Inc. |
Antisense Oligonucleotides Targeting ATXN3
|
|
WO2022133278A2
(en)
|
2020-12-18 |
2022-06-23 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating factor xii
|
|
AR124378A1
(es)
|
2020-12-18 |
2023-03-22 |
Hoffmann La Roche |
Oligonucleótidos antisentido dirigida a progranulina
|
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
EP4284513A1
(en)
|
2021-01-26 |
2023-12-06 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
WO2022189363A1
(en)
|
2021-03-08 |
2022-09-15 |
Les Laboratoires Servier |
Antisense oligonucleotides for inhibiting alpha-synuclein expression
|
|
WO2022232650A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
CA3222546A1
(en)
|
2021-06-08 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Oligonucleotide progranulin agonists
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
AU2022293556A1
(en)
|
2021-06-18 |
2024-01-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ifnar1 expression
|
|
CN117677699A
(zh)
|
2021-06-23 |
2024-03-08 |
马萨诸塞大学 |
用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物
|
|
EP4363574A1
(en)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023015223A2
(en)
|
2021-08-03 |
2023-02-09 |
Verve Therapeutics, Inc. |
Compositions and methods for targeted rna delivery
|
|
WO2023034561A2
(en)
*
|
2021-09-02 |
2023-03-09 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
CN118265544A
(zh)
|
2021-09-16 |
2024-06-28 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
CN118318042A
(zh)
|
2021-11-03 |
2024-07-09 |
豪夫迈·罗氏有限公司 |
用于调节载脂蛋白e4表达的寡核苷酸
|
|
KR20240101580A9
(ko)
|
2021-11-11 |
2025-12-10 |
에프. 호프만-라 로슈 아게 |
Hbv 치료를 위한 약학 조합물
|
|
EP4441224A4
(en)
*
|
2021-12-03 |
2026-03-11 |
Quralis Corp |
Antisense oligonucleotides with modified skeletal chemicals
|
|
WO2023104693A1
(en)
|
2021-12-07 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
JP2024546887A
(ja)
|
2021-12-17 |
2024-12-26 |
ジェネンテック， インコーポレイテッド |
オリゴヌクレオチドｇｂａアゴニスト
|
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
AR128558A1
(es)
|
2022-02-21 |
2024-05-22 |
Hoffmann La Roche |
Oligonucleótido antisentido
|
|
US20250188477A1
(en)
|
2022-03-16 |
2025-06-12 |
Daiichi Sankyo Company, Limited |
CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY
|
|
EP4495240A1
(en)
|
2022-03-16 |
2025-01-22 |
Daiichi Sankyo Company, Limited |
Sirna for suppressing expression of transferrin receptor-2
|
|
CN119173632A
(zh)
|
2022-05-10 |
2024-12-20 |
豪夫迈·罗氏有限公司 |
靶向cfp-elk1基因间区域的反义寡核苷酸
|
|
WO2023222858A1
(en)
|
2022-05-18 |
2023-11-23 |
F. Hoffmann-La Roche Ag |
Improved oligonucleotides targeting rna binding protein sites
|
|
EP4282964A1
(en)
*
|
2022-05-23 |
2023-11-29 |
Universitat de Valéncia |
Oligonucleotides conjugated to oleic acid and uses thereof
|
|
CN119365600A
(zh)
|
2022-06-17 |
2025-01-24 |
豪夫迈·罗氏有限公司 |
靶向颗粒蛋白前体的反义寡核苷酸
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
KR20250059413A
(ko)
|
2022-09-06 |
2025-05-02 |
에프. 호프만-라 로슈 아게 |
눈에 투여하기 위한 이중 가닥 rna 분자
|
|
JP2025532127A
(ja)
|
2022-09-23 |
2025-09-29 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｍｅｃｐ２発現を低減する化合物及び方法
|
|
KR20250116673A
(ko)
*
|
2022-11-21 |
2025-08-01 |
펩젠 인크. |
세포-침투 펩티드, 그의 접합체 및 그의 사용 방법
|
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
WO2024153586A1
(en)
|
2023-01-16 |
2024-07-25 |
Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
CN120936707A
(zh)
|
2023-01-19 |
2025-11-11 |
奥托斯实验室公司 |
再生因子在器官移植中的用途
|
|
WO2024196893A1
(en)
*
|
2023-03-17 |
2024-09-26 |
Camford Labs Inc. |
Chemically modified nucleotides
|
|
WO2024199445A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Ractigen Therapeutics |
Vehicles for delivering oligonucleotides and methods of use thereof
|
|
EP4705457A2
(en)
|
2023-05-04 |
2026-03-11 |
F. Hoffmann-La Roche AG |
Oligonucleotides capable of upregulating glucocerebrosidase expression
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
TW202516004A
(zh)
|
2023-06-16 |
2025-04-16 |
瑞士商赫孚孟拉羅股份公司 |
調節ｊａｋ１表現之雙股寡核苷酸
|
|
IL326478A
(en)
|
2023-08-16 |
2026-04-01 |
Servier Lab |
Oligonucleotides for modulation of KCNT1 expression
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|
|
WO2026024954A2
(en)
|
2024-07-24 |
2026-01-29 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
EP4711455A1
(en)
|
2024-09-11 |
2026-03-18 |
Aarhus Universitet |
Small artificial rna (smartrna) oligonucleotide for modulating protein expression
|